Neurodegeneration with brain iron accumulation - Clinical syndromes and neuroimaging

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 3, 2012, Pages 350-360

  Schipper, Hyman M ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Ferritin; Iron; Magnetic resonance imaging (MRI); Neurodegeneration with brain iron accumulation (NBIA); Neuroimaging; Syndromes

Indexed keywords

BACLOFEN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; FRATAXIN; FRESH FROZEN PLASMA; IDEBENONE; IRON; PANTOTHENATE KINASE 2; PANTOTHENIC ACID; REACTIVE OXYGEN METABOLITE; UBIQUINONE; ZINC SULFATE;

ACERULOPLASMINEMIA; AGING; ALPHA TOCOPHEROL DEFICIENCY; APOPTOSIS; BASAL GANGLION; BLOOD BRAIN BARRIER; BRAIN LEVEL; CEREBELLUM ATROPHY; CEREBELLUM NUCLEUS; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ECHOGRAPHY; FATTY ACID 2 HYDROXYLASE ASSOCIATED NEURODEGENERATION; FRIEDREICH ATAXIA; GAIT DISORDER; GENE MUTATION; HEMATOLOGIC DISEASE; HEMOCHROMATOSIS; HETEROZYGOSITY; HIPPOCAMPUS; HUMAN; IRON CHELATION; IRON STORAGE; KUFOR RAKEB DISEASE; LIPID PEROXIDATION; MAGNETIC FIELD; MENTAL DETERIORATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; OXIDATIVE STRESS; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PARKINSON DISEASE; PARKINSONISM; PHOSPHOLIPASE A2G6 ASSOCIATED NEURODEGENERATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; RELAXATION TIME; RESTLESS LEGS SYNDROME; REVIEW; SIGNAL TRANSDUCTION; VISUAL DISORDER; WHITE MATTER;

BRAIN; HUMANS; IRON; NEURODEGENERATIVE DISEASES; NEUROIMAGING; NEUROTOXICITY SYNDROMES;

EID: 84856044221     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.06.016     Document Type: Review

References (105)

1. Schipper H.M. Chapter 123. Metal accumulation during aging. Encyclopedia of Neuroscience 2009, 811-818. Academic Press, Oxford. L.R. Squire (Ed.).
2. H.M. Schipper, Redox Neurology, in: K. Pantopoulos, H.M. Schipper (Eds.), Principles of Free Radical Biomedicine, Vol. III, Ch. 10, Nova Science Publishers, Hauppauge NY, in press.
3. Ponka P., Beaumont C., Richardson D.R. Function and regulation of transferrin and ferritin. Semin. Hematol. 1998, 35:35-54.
4. Richardson D.R., Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1997, 1331:1-40.
5. Aisen P., Enns C., Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int. J. Biochem. Cell Biol. 2001, 33:940-959.
6. De Domenico I., McVey Ward D., Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat. Rev. Mol. Cell Biol. 2008, 9:72-81.
7. Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004, 117:285-297.
8. Schipper H.M., Ponka P. Inherited disorders of brain iron homeostasis. Iron Deficiency and Overload: From Basic Biology to Clinical Medicine 2009, 251-276. Human Press Inc., Totowa, NJ. S. Yehudah, D.I. Mostofsky (Eds.).
9. Moos T., Rosengren Nielsen T., Skjorringe T., Morgan E.H. Iron trafficking inside the brain. J. Neurochem. 2007, 103:1730-1740.
10. Schipper H.M. Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res. Rev. 2004, 3:265-301.
11. Johnstone D., Milward E.A. Molecular genetic approaches to understanding the roles and regulation of iron in brain health and disease. J. Neurochem. 2010, 113:1387-1402.
12. Benarroch E.E. Brain iron homeostasis and neurodegenerative disease. Neurology 2009, 72:1436-1440.
13. Connor J.R. Metals and Oxidative Damage in Neurological Disorders 1997, Plenum Press, New York.
14. Li X., Jankovic J., Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J. Neural. Transm. 2011, 118:473-477.
15. Stankiewicz J., Panter S.S., Neema M., Arora A., Batt C.E., Bakshi R. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007, 4:371-386.
16. Peran P., Hagberg G., Luccichenti G., Cherubini A., Brainovich V., Celsis P., Caltagirone C., Sabatini U. Voxel-based analysis of R2* maps in the healthy human brain. J. Magn. Reson. Imaging 2007, 26:1413-1420.
17. Schenck J.F., Zimmerman E.A. High-field magnetic resonance imaging of brain iron: birth of a biomarker?. NMR Biomed. 2004, 17:433-445.
18. Bartzokis G., Beckson M., Hance D.B., Marx P., Foster J.A., Marder S.R. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging 1997, 15:29-35.
19. Bartzokis G., Tishler T.A., Lu P.H., Villablanca P., Altshuler L.L., Carter M., Huang D., Edwards N., Mintz J. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 2007, 28:414-423.
20. Pfefferbaum A., Adalsteinsson E., Rohlfing T., Sullivan E.V. MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. Neuroimage 2009, 47:493-500.
21. Haacke E.M., Ayaz M., Khan A., Manova E.S., Krishnamurthy B., Gollapalli L., Ciulla C., Kim I., Petersen F., Kirsch W. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J. Magn. Reson. Imaging 2007, 26:256-264.
22. Haacke E.M., Xu Y., Cheng Y.C., Reichenbach J.R. Susceptibility weighted imaging (SWI). Magn. Reson. Med. 2004, 52:612-618.
23. Duyn J.H., van Gelderen P., Li T.Q., de Zwart J.A., Koretsky A.P., Fukunaga M. High-field MRI of brain cortical substructure based on signal phase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11796-11801.
24. Bartzokis G., Aravagiri M., Oldendorf W.H., Mintz J., Marder S.R. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn. Reson. Med. 1993, 29:459-464.
25. Jin L., Wang J., Zhao L., Jin H., Fei G., Zhang Y., Zeng M., Zhong C. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011, 134:50-58.
26. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 1958, 3:41-51.
27. Mittal S., Wu Z., Neelavalli J., Haacke E.M. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. Am. J. Neuroradiol. 2009, 30:232-252.
28. Cherubini A., Peran P., Caltagirone C., Sabatini U., Spalletta G. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 2009, 48:29-36.
29. Valdes Hernandez M.C., Jeong T.H., Murray C., Bastin M.E., Chappell F.M., Deary I.J., Wardlaw J.M. Reliability of two techniques for assessing cerebral iron deposits with structural magnetic resonance imaging. J. Magn. Reson. Imaging 2011, 33:54-61.
30. Walter U. Transcranial sonography in brain disorders with trace metal accumulation. Int. Rev. Neurobiol. 2010, 90:166-178.
31. Berg D., Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov. Disord. 2006, 21:1299-1310.
32. Gille G., Reichmann H. Iron-dependent functions of mitochondria-relation to neurodegeneration. J. Neural Transm. 2011, 118:349-359.
33. Felitti V.J., Beutler E. New developments in hereditary hemochromatosis. Am. J. Med. Sci. 1999, 318:257-268.
34. Pandolfo M. Friedreich ataxia. Arch. Neurol. 2008, 65:1296-1303.
35. Babady N.E., Carelle N., Wells R.D., Rouault T.A., Hirano M., Lynch D.R., Delatycki M.B., Wilson R.B., Isaya G., Puccio H. Advancements in the pathophysiology of Friedreich's ataxia and new prospects for treatments. Mol. Genet. Metab. 2007, 92:23-35.
36. Lamarche J.B., Cote M., Lemieux B. The cardiomyopathy of Friedreich's ataxia morphological observations in 3 cases. Can. J. Neurol. Sci. 1980, 7:389-396.
37. Waldvogel D., van Gelderen P., Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann. Neurol. 1999, 46:123-125.
38. Frauscher B., Hering S., Hogl B., Gschliesser V., Ulmer H., Poewe W., Boesch S.M. Restless legs syndrome in Friedreich ataxia: a polysomnographic study. Mov. Disord. 2011, 26:302-306.
39. Becker E., Richardson D.R. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int. J. Biochem. Cell Biol. 2001, 33:1-10.
40. Pandolfo M. Friedreich's ataxia: clinical aspects and pathogenesis. Semin. Neurol. 1999, 19:311-321.
41. Hart P.E., Lodi R., Rajagopalan B., Bradley J.L., Crilley J.G., Turner C., Blamire A.M., Manners D., Styles P., Schapira A.H., Cooper J.M. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 2005, 62:621-626.
42. Wilson R.B. Iron dysregulation in Friedreich ataxia. Semin. Pediatr. Neurol. 2006, 13:166-175.
43. Boddaert N., Le Quan Sang K.H., Rotig A., Leroy-Willig A., Gallet S., Brunelle F., Sidi D., Thalabard J.C., Munnich A., Cabantchik Z.I. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
44. Velasco-Sanchez D., Aracil A., Montero R., Mas A., Jimenez L., O'Callaghan M., Tondo M., Capdevila A., Blanch J., Artuch R., Pineda M. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011, 10:1-8.
45. Hayflick S.J. Neurodegeneration with brain iron accumulation: from genes to pathogenesis. Semin. Pediatr. Neurol. 2006, 13:182-185.
46. Johnson M.A., Kuo Y.M., Westaway S.K., Parker S.M., Ching K.H., Gitschier J., Hayflick S.J. Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann. N. Y. Acad. Sci. 2004, 1012:282-298.
47. Zhou B., Westaway S.K., Levinson B., Johnson M.A., Gitschier J., Hayflick S.J. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet. 2001, 28:345-349.
48. Rump P., Lemmink H.H., Verschuuren-Bemelmans C.C., Grootscholten P.M., Fock J.M., Hayflick S.J., Westaway S.K., Vos Y.J., van Essen A.J. A novel 3-bp deletion in the PANK2 gene of Dutch patients with pantothenate kinase-associated neurodegeneration: evidence for a founder effect. Neurogenetics 2005, 6:201-207.
49. Hayflick S.J. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr. Opin. Pediatr. 2003, 15:572-577.
50. Swaiman K.F. Hallervorden-Spatz syndrome. Pediatr. Neurol. 2001, 25:102-108.
51. Walterfang M., Evans A., Looi J., Jung H.H., Danek A., Walker R., Velakoulis D. The Neuropsychiatry of neuroacanthocytosis syndromes. Neurosci. Biobehav. Rev. 2011, 35:1275-1283.
52. Mak C.M., Sheng B., Lee H.H., Lau K.K., Chan W.T., Lam C.W., Chan Y.W. Young-onset Parkinsonism in a Hong Kong Chinese man with adult-onset Hallervorden-Spatz syndrome. Int. J. Neurosci. 2011, 121:224-227.
53. Vasconcelos O.M., Harter D.H., Duffy C., McDonough B., Seidman J.G., Seidman C.E., Campbell W.W. Adult Hallervorden-Spatz syndrome simulating amyotrophic lateral sclerosis. Muscle Nerve 2003, 28:118-122.
54. Seo J.H., Song S.K., Lee P.H. A novel PANK2 mutation in a patient with atypical pantothenate-kinase-associated neurodegeneration presenting with adult-onset Parkinsonism. J. Clin. Neurol. 2009, 5:192-194.
55. Ching K.H., Westaway S.K., Gitschier J., Higgins J.J., Hayflick S.J. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002, 58:1673-1674.
56. Savoiardo M., Halliday W.C., Nardocci N., Strada L., D'Incerti L., Angelini L., Rumi V., Tesoro-Tess J.D. Hallervorden-Spatz disease: MR and pathologic findings. AJNR Am. J. Neuroradiol. 1993, 14:155-162.
57. Swaiman K.F., Smith S.A., Trock G.L., Siddiqui A.R. Sea-blue histiocytes, lymphocytic cytosomes, movement disorder and 59Fe-uptake in basal ganglia: Hallervorden-Spatz disease or ceroid storage disease with abnormal isotope scan?. Neurology 1983, 33:301-305.
58. Zupanc M.L., Chun R.W., Gilbert-Barness E.F. Osmiophilic deposits in cytosomes in Hallervorden-Spatz syndrome. Pediatr. Neurol. 1990, 6:349-352.
59. Perry T.L., Norman M.G., Yong V.W., Whiting S., Crichton J.U., Hansen S., Kish S.J. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann. Neurol. 1985, 18:482-489.
60. Yoon S.J., Koh Y.H., Floyd R.A., Park J.W. Copper, zinc superoxide dismutase enhances DNA damage and mutagenicity induced by cysteine/iron. Mutat. Res. 2000, 448:97-104.
61. Schneider S.A., Bhatia K.P., Hardy J. Complicated recessive dystonia parkinsonism syndromes. Mov. Disord. 2009, 24:490-499.
62. Justesen C.R., Penn R.D., Kroin J.S., Egel R.T. Stereotactic pallidotomy in a child with Hallervorden-Spatz disease. Case report. J. Neurosurg. 1999, 90:551-554.
63. Zimmerman E.A., Schenck J.F. Neurodegeneration with Brain Iron Accumulation 2007, MedLink Neurology, in, MedLink Neurology http://www.medlink.com/cip.asp?UID=mlt002h8&src=Search&ref=19850753. http://www.medlink.com/cip.asp?UID=mlt002h8&src=Search&ref=19850753.
64. Morgan N.V., Westaway S.K., Morton J.E., Gregory A., Gissen P., Sonek S., Cangul H., Coryell J., Canham N., Nardocci N., Zorzi G., Pasha S., Rodriguez D., Desguerre I., Mubaidin A., Bertini E., Trembath R.C., Simonati A., Schanen C., Johnson C.A., Levinson B., Woods C.G., Wilmot B., Kramer P., Gitschier J., Maher E.R., Hayflick S.J. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 2006, 38:752-754.
65. Yoshino H., Tomiyama H., Tachibana N., Ogaki K., Li Y., Funayama M., Hashimoto T., Takashima S., Hattori N. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010, 75:1356-1361.
66. Gregory A., Westaway S.K., Holm I.E., Kotzbauer P.T., Hogarth P., Sonek S., Coryell J.C., Nguyen T.M., Nardocci N., Zorzi G., Rodriguez D., Desguerre I., Bertini E., Simonati A., Levinson B., Dias C., Barbot C., Carrilho I., Santos M., Malik I., Gitschier J., Hayflick S.J. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008, 71:1402-1409.
67. Balsinde J., Balboa M.A. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell. Signal. 2005, 17:1052-1062.
68. Aicardi J., Castelein P. Infantile neuroaxonal dystrophy. Brain 1979, 102:727-748.
69. Mubaidin A., Roberts E., Hampshire D., Dehyyat M., Shurbaji A., Mubaidien M., Jamil A., Al-Din A., Kurdi A., Woods C.G. Karak syndrome: a novel degenerative disorder of the basal ganglia and cerebellum. J. Med. Genet. 2003, 40:543-546.
70. Kruer M.C., Paisan-Ruiz C., Boddaert N., Yoon M.Y., Hama H., Gregory A., Malandrini A., Woltjer R.L., Munnich A., Gobin S., Polster B.J., Palmeri S., Edvardson S., Hardy J., Houlden H., Hayflick S.J. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann. Neurol. 2010, 68:611-618.
71. Edvardson S., Hama H., Shaag A., Gomori J.M., Berger I., Soffer D., Korman S.H., Taustein I., Saada A., Elpeleg O. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am. J. Hum. Genet. 2008, 83:643-648.
72. Dick K.J., Eckhardt M., Paisan-Ruiz C., Alshehhi A.A., Proukakis C., Sibtain N.A., Maier H., Sharifi R., Patton M.A., Bashir W., Koul R., Raeburn S., Gieselmann V., Houlden H., Crosby A.H. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum. Mutat. 2010, 31:E1251-E1260.
73. Hama H. Fatty acid 2-Hydroxylation in mammalian sphingolipid biology. Biochim. Biophys. Acta 2010, 1801:405-414.
74. Najim al-Din A.S., Wriekat A., Mubaidin A., Dasouki M., Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 1994, 89:347-352.
75. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., Goebel I., Mubaidin A.F., Wriekat A.L., Roeper J., Al-Din A., Hillmer A.M., Karsak M., Liss B., Woods C.G., Behrens M.I., Kubisch C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 2006, 38:1184-1191.
76. Gitler A.D., Chesi A., Geddie M.L., Strathearn K.E., Hamamichi S., Hill K.J., Caldwell K.A., Caldwell G.A., Cooper A.A., Rochet J.C., Lindquist S. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 2009, 41:308-315.
77. Schneider S.A., Paisan-Ruiz C., Quinn N.P., Lees A.J., Houlden H., Hardy J., Bhatia K.P. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov. Disord. 2010, 25:979-984.
78. Bruggemann N., Hagenah J., Reetz K., Schmidt A., Kasten M., Buchmann I., Eckerle S., Bahre M., Munchau A., Djarmati A., van der Vegt J., Siebner H., Binkofski F., Ramirez A., Behrens M.I., Klein C. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch. Neurol. 2010, 67:1357-1363.
79. Hellman N.E., Gitlin J.D. Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 2002, 22:439-458.
80. Nittis T., Gitlin J.D. The copper-iron connection: hereditary aceruloplasminemia. Semin. Hematol. 2002, 39:282-289.
81. Patel B.N., David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J. Biol. Chem. 1997, 272:20185-20190.
82. Miyajima H., Nishimura Y., Mizoguchi K., Sakamoto M., Shimizu T., Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 1987, 37:761-767.
83. Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., MacGillivray R.T., Gitlin J.D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:2539-2543.
84. Daimon M., Kato T., Kawanami T., Tominaga M., Igarashi M., Yamatani K., Sasaki H. A nonsense mutation of the ceruloplasmin gene in hereditary ceruloplasmin deficiency with diabetes mellitus. Biochem. Biophys. Res. Commun. 1995, 217:89-95.
85. Okamoto N., Wada S., Oga T., Kawabata Y., Baba Y., Habu D., Takeda Z., Wada Y. Hereditary ceruloplasmin deficiency with hemosiderosis. Hum. Genet. 1996, 97:755-758.
86. Yoshida K., Furihata K., Takeda S., Nakamura A., Yamamoto K., Morita H., Hiyamuta S., Ikeda S., Shimizu N., Yanagisawa N. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat. Genet. 1995, 9:267-272.
87. Miyajima H., Kono S., Takahashi Y., Sugimoto M., Sakamoto M., Sakai N. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 2001, 57:2205-2210.
88. Fasano A., Colosimo C., Miyajima H., Tonali P.A., Re T.J., Bentivoglio A.R. Aceruloplasminemia: a novel mutation in a family with marked phenotypic variability. Mov. Disord. 2008, 23:751-755.
89. Yonekawa M., Okabe T., Asamoto Y., Ohta M. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma. Eur. Neurol. 1999, 42:157-162.
90. McNeill A., Birchall D., Hayflick S.J., Gregory A., Schenk J.F., Zimmerman E.A., Shang H., Miyajima H., Chinnery P.F. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008, 70:1614-1619.
91. Arosio P., Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radic. Biol. Med. 2002, 33:457-463.
92. Curtis A.R., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A.P., McHale D.P., Hay D., Barker W.A., Markham A.F., Bates D., Curtis A., Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 2001, 28:350-354.
93. Burn J., Chinnery P.F. Neuroferritinopathy. Semin. Pediatr. Neurol. 2006, 13:176-181.
94. Chinnery P.F., Crompton D.E., Birchall D., Jackson M.J., Coulthard A., Lombes A., Quinn N., Wills A., Fletcher N., Mottershead J.P., Cooper P., Kellett M., Bates D., Burn J. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007, 130:110-119.
95. Wills A.J., Sawle G.V., Guilbert P.R., Curtis A.R. Palatal tremor and cognitive decline in neuroferritinopathy. J. Neurol. Neurosurg. Psychiatry 2002, 73:91-92.
96. Chinnery P.F., Curtis A.R., Fey C., Coulthard A., Crompton D., Curtis A., Lombes A., Burn J. Neuroferritinopathy in a French family with late onset dominant dystonia. J. Med. Genet. 2003, 40:e69.
97. Mancuso M., Davidzon G., Kurlan R.M., Tawil R., Bonilla E., Di Mauro S., Powers J.M. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J. Neuropathol. Exp. Neurol. 2005, 64:280-294.
98. Levi S., Cozzi A., Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract. Res. Clin. Haematol. 2005, 18:265-276.
99. Vidal R., Ghetti B., Takao M., Brefel-Courbon C., Uro-Coste E., Glazier B.S., Siani V., Benson M.D., Calvas P., Miravalle L., Rascol O., Delisle M.B. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J. Neuropathol. Exp. Neurol. 2004, 63:363-380.
100. Schroder J.M. Ferritinopathy: diagnosis by muscle or nerve biopsy, with a note on other nuclear inclusion body diseases. Acta Neuropathol. 2005, 109:109-114.
101. Henri-Bhargava A., Melmed C., Glikstein R., Schipper H.M. Neurologic impairment due to vitamin E and copper deficiencies in celiac disease. Neurology 2008, 71:860-861.
102. van der Knaap M.S., Valk J., de Neeling N., Nauta J.J. Pattern recognition in magnetic resonance imaging of white matter disorders in children and young adults. Neuroradiology 1991, 33:478-493.
103. Rutledge J.N., Hilal S.K., Silver A.J., Defendini R., Fahn S. Magnetic resonance imaging of dystonic states. Adv. Neurol. 1988, 50:265-275.
104. Hellier K.D., Hatchwell E., Duncombe A.S., Kew J., Hammans S.R. X-linked sideroblastic anaemia with ataxia: another mitochondrial disease?. J. Neurol. Neurosurg. Psychiatry 2001, 70:65-69.
105. Castelnau P., Zilbovicius M., Ribeiro M.J., Hertz-Pannier L., Ogier H., Evrard P. Striatal and pontocerebellar hypoperfusion in Hallervorden-Spatz syndrome. Pediatr. Neurol. 2001, 25:170-174.